Home » Stocks » Horizon Therapeutics

Horizon Therapeutics PLC (HZNP)

Stock Price: $76.06 USD 3.84 (5.32%)
Updated Aug 7, 2020 4:00 PM EDT - Market closed
After-hours: $75.86 -0.20 (-0.26%) Aug 7, 7:22 PM

Stock Price Chart

Key Info

Market Cap 15.18B
Revenue (ttm) 1.52B
Net Income (ttm) 517.40M
Shares Out 206.46M
EPS (ttm) 2.55
PE Ratio 29.83
Forward PE 19.80
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 7, 2020
Last Price $76.06
Previous Close $72.22
Change ($) 3.84
Change (%) 5.32%
Day's Open 71.79
Day's Range 71.60 - 78.93
Day's Volume 11,514,692
52-Week Range 23.81 - 78.93

More Stats

Market Cap 15.18B
Enterprise Value 15.64B
Earnings Date (est) Nov 9, 2020
Ex-Dividend Date n/a
Shares Outstanding 206.46M
Float 191.85M
EPS (basic) 2.85
EPS (diluted) 2.55
FCF / Share 0.96
Dividend n/a
Dividend Yield n/a
Earnings Yield 3.35%
FCF Yield 1.22%
Payout Ratio n/a
Shares Short 9.23M
Short Ratio 2.27
Short % of Float 3.41%
Beta 1.23
PE Ratio 29.83
Forward PE 19.80
P/FCF Ratio 82.09
PS Ratio 10.00
PB Ratio 6.84
Revenue 1.52B
Operating Income 125.88M
Net Income 517.40M
Free Cash Flow 184.94M
Net Cash -455.14M
Net Cash / Share -2.28
Gross Margin 61.80%
Operating Margin 8.29%
Profit Margin 34.10%
FCF Margin 12.19%
ROA 1.89%
ROE 26.65%
ROIC 3.80%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (9)

Buy 8
Overweight 0
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$91.89*
(20.81% upside)
Low
42.0
Current: $76.06
High
123.0
Target: 91.89
*Average 12-month price target from 9 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue1,3001,2081,05698175729774.0218.846.932.38
Revenue Growth7.66%14.33%7.66%29.6%154.94%301.2%292.78%172.04%191.54%-
Gross Profit93881656358953821859.396.97-0.34-1.89
Operating Income12638.75-339-13945.08-8.49-42.85-78.87-121-43.75
Net Income573-38.38-350-16639.53-264-149-87.79-113-27.07
Shares Outstanding18316616316114983.7563.6638.879.011.28
Earnings Per Share2.90-0.23-2.15-1.030.25-3.15-2.34-2.26-12.56-21.16
Operating Cash Flow42619528436919427.55-54.29-76.64-41.54-37.53
Capital Expenditures-17.8639.65-4.34-15.73-7.16-3.50-1.20-1.34-1.60-0.71
Free Cash Flow40823428035418724.05-55.49-77.98-43.14-38.25
Cash & Equivalents1,08096275851686122081.2210518.725.58
Total Debt1,3531,8971,9021,8071,13734611148.8019.4424.62
Net Cash / Debt-273-935-1,144-1,291-275-126-29.5456.09-0.72-19.03
Assets4,4363,9424,2024,2923,0591,114253194101162
Liabilities2,2512,7523,2013,0281,74557430288.0155.1764.63
Book Value2,1851,1901,0011,2641,313540-49.0810645.9197.06
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Horizon Therapeutics PLC
Country Ireland
Employees 1,225
CEO Timothy P. Walbert

Stock Information

Ticker Symbol HZNP
Stock Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Unique Identifier NASDAQ: HZNP
IPO Date July 28, 2011

Description

Horizon Therapeutics Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. Its orphan and rheumatology marketed medicines include KRYSTEXXA, a medicine for the treatment of uncontrolled gout; RAVICTI for use as a nitrogen-binding agent for chronic management of adult and pediatric patients; PROCYSBI for nephropathic cystinosis, a rare and life-threatening metabolic disorder; ACTIMMUNE for chronic granulomatous disease; RAYOS for the treatment of multiple conditions, rheumatoid arthritis; BUPHENYL tablets for oral administration and BUPHENYL powder for oral, nasogastric, or gastrostomy tube administration; and QUINSAIR, a formulation of the antibiotic drug levofloxacin for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis. The company's primary care marketed medicines comprise PENNSAID 2% that is indicated for the treatment of pain of osteoarthritis of the knees; DUEXIS for the relief of signs and symptoms of RA and OA, and to decrease the risk of developing upper-GI ulcers; VIMOVO for the relief of signs and symptoms of OA, RA, and AS and to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers; and MIGERGOT, a therapy to abort or prevent vascular headaches, such as migraines and migraine variants. It has collaboration agreements with Alliance for Lupus Research, Syneos Health, Inc., and HemoShear Therapeutics, LLC. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland.